Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
Castle Biosciences (CSTL) is strengthening its commitment to esophageal cancer awareness through partnerships with key organizations during Esophageal Cancer Awareness Month in April 2025. The company is collaborating with the Esophageal Cancer Action Network (ECAN), the American Foregut Society (AFS), and The Gut Doctor Podcast.
With esophageal cancer's five-year survival rate at only 20%, early detection is crucial. The company's TissueCypher® test helps identify which Barrett's esophagus patients among the 1.5 million U.S. cases are at risk of progressing to cancer, affecting approximately 0.5% of cases.
Key initiatives include:
- ECAN partnership featuring digital media campaigns and awareness kits
- Special episode on AFS's All Fore Guts! podcast about screening importance
- Collaboration with The Gut Doctor Podcast discussing risk factors and treatment
Castle Biosciences (CSTL) sta rafforzando il suo impegno per la sensibilizzazione sul cancro esofageo attraverso partnership con organizzazioni chiave durante il Mese della Consapevolezza sul Cancro Esofageo nell'aprile 2025. L'azienda collabora con il Esophageal Cancer Action Network (ECAN), l'American Foregut Society (AFS) e il podcast The Gut Doctor.
Con un tasso di sopravvivenza a cinque anni per il cancro esofageo pari solo al 20%, la diagnosi precoce è fondamentale. Il test TissueCypher® dell'azienda aiuta a identificare quali pazienti con esofago di Barrett tra i 1,5 milioni di casi negli Stati Uniti sono a rischio di progressione verso il cancro, che colpisce circa lo 0,5% dei casi.
Le iniziative chiave includono:
- Partnership con ECAN con campagne sui media digitali e kit di sensibilizzazione
- Episodio speciale sul podcast All Fore Guts! di AFS riguardo l'importanza dello screening
- Collaborazione con il podcast The Gut Doctor per discutere fattori di rischio e trattamenti
Castle Biosciences (CSTL) está fortaleciendo su compromiso con la concienciación sobre el cáncer esofágico a través de asociaciones con organizaciones clave durante el Mes de Concienciación sobre el Cáncer Esofágico en abril de 2025. La empresa está colaborando con la Esophageal Cancer Action Network (ECAN), la American Foregut Society (AFS) y el podcast The Gut Doctor.
Con una tasa de supervivencia a cinco años para el cáncer esofágico de solo el 20%, la detección temprana es crucial. La prueba TissueCypher® de la empresa ayuda a identificar qué pacientes con esófago de Barrett entre los 1.5 millones de casos en EE. UU. están en riesgo de progresar a cáncer, afectando aproximadamente al 0.5% de los casos.
Las iniciativas clave incluyen:
- Asociación con ECAN que presenta campañas de medios digitales y kits de concienciación
- Episodio especial en el podcast All Fore Guts! de AFS sobre la importancia del screening
- Colaboración con el podcast The Gut Doctor discutiendo factores de riesgo y tratamiento
Castle Biosciences (CSTL)는 2025년 4월 식도암 인식의 달 동안 주요 기관과의 파트너십을 통해 식도암 인식에 대한 약속을 강화하고 있습니다. 이 회사는 Esophageal Cancer Action Network (ECAN), American Foregut Society (AFS), 그리고 The Gut Doctor Podcast와 협력하고 있습니다.
식도암의 5년 생존율이 겨우 20%인 만큼 조기 발견이 매우 중요합니다. 이 회사의 TissueCypher® 테스트는 미국의 150만 건의 경우 중 어떤 Barrett 식도 환자가 암으로 진행될 위험이 있는지를 식별하는 데 도움을 줍니다. 이는 약 0.5%의 경우에 해당합니다.
주요 이니셔티브는 다음과 같습니다:
- 디지털 미디어 캠페인 및 인식 키트를 특징으로 하는 ECAN 파트너십
- 선별 검사의 중요성에 대한 AFS의 All Fore Guts! 팟캐스트의 특별 에피소드
- 위험 요소 및 치료에 대해 논의하는 The Gut Doctor Podcast와의 협력
Castle Biosciences (CSTL) renforce son engagement en faveur de la sensibilisation au cancer de l'œsophage grâce à des partenariats avec des organisations clés pendant le Mois de sensibilisation au cancer de l'œsophage en avril 2025. L'entreprise collabore avec le Esophageal Cancer Action Network (ECAN), l'American Foregut Society (AFS) et le podcast The Gut Doctor.
Avec un taux de survie à cinq ans pour le cancer de l'œsophage de seulement 20 %, la détection précoce est cruciale. Le test TissueCypher® de l'entreprise aide à identifier quels patients atteints d'œsophage de Barrett parmi les 1,5 million de cas aux États-Unis sont à risque de progression vers le cancer, touchant environ 0,5 % des cas.
Les initiatives clés incluent :
- Partenariat avec ECAN incluant des campagnes de médias numériques et des kits de sensibilisation
- Épisode spécial sur le podcast All Fore Guts! de l'AFS concernant l'importance du dépistage
- Collaboration avec le podcast The Gut Doctor discutant des facteurs de risque et des traitements
Castle Biosciences (CSTL) verstärkt sein Engagement für das Bewusstsein über Speiseröhrenkrebs durch Partnerschaften mit wichtigen Organisationen während des Monats zur Sensibilisierung für Speiseröhrenkrebs im April 2025. Das Unternehmen arbeitet mit dem Esophageal Cancer Action Network (ECAN), der American Foregut Society (AFS) und dem Podcast The Gut Doctor zusammen.
Da die Fünf-Jahres-Überlebensrate bei Speiseröhrenkrebs nur 20% beträgt, ist eine frühzeitige Erkennung entscheidend. Der TissueCypher®-Test des Unternehmens hilft dabei, herauszufinden, welche Barrett-Ösophagus-Patienten unter den 1,5 Millionen Fällen in den USA ein Risiko für die Krebsentwicklung haben, was etwa 0,5% der Fälle betrifft.
Wichtige Initiativen sind:
- Partnerschaft mit ECAN, die digitale Medienkampagnen und Sensibilisierungskits umfasst
- Besondere Episode im Podcast All Fore Guts! von AFS über die Bedeutung des Screenings
- Zusammenarbeit mit dem Podcast The Gut Doctor, um Risikofaktoren und Behandlungen zu besprechen
- None.
- None.
FRIENDSWOOD, Texas, April 08, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is supporting key educational programs and initiatives throughout the month of April in recognition of Esophageal Cancer Awareness Month. The Company is proudly collaborating with the Esophageal Cancer Action Network (ECAN), the American Foregut Society (AFS) and The Gut Doctor PodcastLLC to promote esophageal cancer prevention, education and advocacy.
“As esophageal cancer is often diagnosed in its late stages, its five-year survival rate remains alarmingly low at around
Detection of esophageal cancer and its precursor, Barrett's esophagus (BE), presents significant challenges because the main symptoms — heartburn and gastroesophageal reflux disease (GERD) —commonly occur in many less serious conditions that typically don't warrant concern. Doctors have very good methods to eliminate precancerous cells in BE patients at risk of developing cancer. The challenge, however, is finding which BE patients among the 1.5 million in the U.S. with the condition are in the
Esophageal Cancer Action Network (ECAN)
Castle is collaborating with ECAN through a dedicated Esophageal Cancer Awareness Month sponsorship that encompasses a digital media campaign and awareness kits containing brochures, posters and wrist bands that will be distributed to ECAN supporters seeking to raise awareness about esophageal cancer. The media campaign will emphasize several key points: 1) the link between reflux and cancer, 2) esophageal cancer is preventable, and 3) new technology creates vast opportunities to save lives, particularly in the areas of screening/detection, risk stratification, diagnostics and treatment. Additionally, the campaign will focus on human interest stories featuring those who have been affected by esophageal cancer and experienced this alarming diagnosis.
“Awareness is key to ending this devastating disease that is the fastest increasing cancer diagnosis in American men today and has tripled among young people in recent decades,”2,3 said Mindy Mintz Mordecai, founder, president and chief executive officer of ECAN. “The heart of our mission at ECAN is to save lives, and we are grateful for the support of our corporate partners and our many supporters who help us carry out this mission through education, prevention and awareness initiatives.”
All Fore Guts! An American Foregut Society Podcast
Castle teamed up with the American Foregut Society (AFS) for a special All Fore Guts! podcast episode, AFS Celebrates Esophageal Cancer Awareness Month — GET SCREENED, which launched April 1. Moderated by AFS President and Co-Founder Dan Lister, M.D., FACS, FAFS, the episode features a discussion with ECAN’s Mordecai and John C. Lipham, M.D., chairman of ECAN’s board of directors, chief of the division of upper GI and general surgery, and professor of surgery at the Keck School of Medicine of USC, highlighting the importance of esophageal cancer screening. Listen to the episode on the American Foregut Society’s website or stream it on Spotify.
The Gut Doctor PodcastLLC
Hosted by Neil D. Parikh, M.D., a community gastroenterologist in Connecticut, The Gut Doctor Podcast provides general education around common gut-related topics through engaging conversations with gastroenterological specialists. For an April episode, Castle collaborated with Parikh and J. George Sun, M.D., a gastroenterologist with Digestive Health Associates in Houston, to discuss esophageal cancer, common risk factors and treatment to raise awareness around the disease. The episode will be available at The Gut Doctor Podcast and through major podcast streaming platforms.
About Esophageal Cancer Action Network
The Esophageal Cancer Action Network (ECAN) is a non-profit, 501 (c)(3) organization supporting esophageal cancer patients and their families. ECAN started Esophageal Cancer Awareness Month in 2009 in support of its mission to save lives by 1) promoting early detection by increasing awareness about the link between reflux disease and cancer, 2) supporting medical innovation to prevent, detect, treat and cure esophageal cancer and 3) providing patients and families with the latest, most reliable medical information and compassionate support. ECAN’s relentless advocacy has increased the federal budget for Esophageal Cancer research by more than
About All Fore Guts! Podcast
Hosted by the American Foregut Society (AFS), the All Fore Guts! Podcast brings gastroenterologists and surgeons together to discuss common foregut conditions. Episodes can be found on the AFS website or on Spotify. AFS is the only society where GIs and surgeons collaborate to personalize treatment and improve patient outcomes in foregut disease. Visit https://www.americanforegutsociety.org/ for more information.
About The Gut Doctor PodcastLLC
The Gut Doctor Podcast is hosted by Neil D. Parikh, M.D., a community gastroenterologist in Connecticut, and discusses common gut topics in a patient-friendly manner. Dr. Parikh interviews fellow GI specialists to provide a better understanding for the general public and medical providers and also features episodes on food as medicine as the worlds of culinary medicine and gastrointestinal health intertwine. Access episodes online at https://thegutdoctor.buzzsprout.com/ and via various podcast streaming platforms.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning: Castle’s ability to raise awareness of esophageal cancer risk factors and provide meaningful support to patients and healthcare professionals; and TissueCypher’s ability to (i) predict a patient’s individual risk of progression to high-grade dysplasia or esophageal cancer and (ii) help physicians prevent the development of life-threatening cancer in BE patients. The words “believe,” “can” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.
1. Center for Cancer Research at the National Cancer Institute (National Institutes of Health); https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-digestive-system-tumors/esophageal; accessed 3/26/25
2. Esophageal Cancer Action Network; https://ecan.org/; accessed 3/26/25
3. Mayo Clinic: Young-onset esophageal adenocarcinoma: Results from a population-based study; https://www.mayoclinic.org/medical-professionals/digestive-diseases/news/young-onset-esophageal-adenocarcinoma-results-from-a-population-based-study/mac-20511018; accessed 3/26/25
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences, Inc.
FAQ
What is the current survival rate for esophageal cancer according to CSTL's 2025 report?
How many Barrett's esophagus patients in the US are at risk of developing cancer according to CSTL?
What is TissueCypher and how does it help in esophageal cancer detection?
What initiatives is CSTL implementing for Esophageal Cancer Awareness Month in April 2025?
What are the main symptoms of esophageal cancer according to Castle Biosciences?
